Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fulcrum Therapeutics (FULC) Return on Capital Employed (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Return on Capital Employed for 7 consecutive years, with 0.31% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Capital Employed rose 10.0% to 0.31% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.31%, a 10.0% increase, with the full-year FY2025 number at 0.28%, down 19.0% from a year prior.
  • Return on Capital Employed was 0.31% for Q4 2025 at Fulcrum Therapeutics, up from 0.39% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.31% in Q4 2025 to a low of 0.59% in Q2 2021.
  • A 5-year average of 0.44% and a median of 0.42% in 2021 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: grew 30bps in 2021, then decreased -8bps in 2024.
  • Fulcrum Therapeutics' Return on Capital Employed stood at 0.36% in 2021, then crashed by -57bps to 0.56% in 2022, then increased by 26bps to 0.42% in 2023, then rose by 4bps to 0.4% in 2024, then grew by 24bps to 0.31% in 2025.
  • Per Business Quant, the three most recent readings for FULC's Return on Capital Employed are 0.31% (Q4 2025), 0.39% (Q3 2025), and 0.39% (Q2 2025).